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Macrocyclic inhibitorsThe ﬁrst structural characterization of the genotype 3a Hepatitis C Virus NS3 protease is reported, providing
insight into the differential susceptibility of 1b and 3a proteases to certain inhibitors. Interaction of the 3a
NS3 protease with a P2–P4 macrocyclic and a linear phenethylamide inhibitor was investigated. In addition,
the effect of the NS4A cofactor binding on the conformation of the protease was analyzed. Complexation of
NS3 with the phenethylamide inhibitor signiﬁcantly stabilizes the protease but binding does not involve
residues 168 and 123, two key amino acids underlying the different inhibition of genotype 1b vs. 3a
proteases by P2–P4 macrocycles. Therefore, we studied the dynamic behavior of these two residues in the
phenethylamide complex, serving as a model of the situation in the apo 3a protein, in order to explore the
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Hepatitis C Virus (HCV) is a pathogen with 3% average infection
prevalence, leading to ∼170 million people infected worldwide
(Wasley and Alter, 2000). A reduced transmission and improved
therapeutic strategies for treating infected patients followed the
discovery of the virus in 1989. However, current therapy is inadequate
and development of resistance is foreseen as a major obstacle for
emerging medications (De Francesco and Migliaccio, 2005). HCV
displays an extensive genome heterogeneity, and to date six
genotypes (1–6) and more than 50 subtypes (1a, 1b, 1c, and so
forth) have been described (Bukh et al., 1995). Although genotype 1
accounts for ∼70% of the infections in industrialized countries,
genotypes 2 and 3 also have wide distributions, and in particular
subtype 3a is common among intravenous drug users in the United
States and Europe (Nolte, 2001; Pawlotsky, 2003).
The highest positive response rates to antiviral therapy for the
treatment of chronic Hepatitis C have been achieved using thecombination of peginterferon and ribavirin. The major determinant of
therapeutic outcome is the HCV genotype (Di Bisceglie and Hoofnagle,
2002): patients infected with genotype 1 achieve response rates of
40% to 45%, compared with rates approaching 80% for those infected
with genotypes 2 or 3. This fact and the high prevalence of genotype 1
have prompted many pharmaceutical companies to concentrate their
efforts in the development of new antiviral agents using viral protein
targets of genotype 1.
The HCV genome encodes a single polyprotein of about 3000
amino acid residues containing four structural proteins (Core–E1–E2–
p7) and six non-structural proteins (NS2–NS3–NS4A–NS4B–NS5A–
NS5B) (Reed and Rice, 2000). The NS3 protein shows both protease
and helicase activities. The N-terminal third of NS3 (residues 1–180)
constitutes a chymotrypsin-like serine protease domain (NS3p)
which, together with the cofactor NS4A, is responsible for the
cleavage of the non-structural proteins NS3–NS5B (Reed and Rice,
2000). In addition, NS3 is used by the virus to antagonize the host cell
innate immune response by cleaving CARDIF and TRIF, two critical
components by which the cells sense the invasion by viral pathogens
and trigger the induction of the antiviral state (Gale and Froy, 2005).
As a result of its central role in the viral life cycle, NS3p has been
chosen as one of the major targets for the development of antiviral
agents (De Francesco and Carﬁ, 2007).
In the past several years, signiﬁcant progress has been made in
developing inhibitors of the HCV NS3/NS4A protease. An important
early observation was that the N-terminal cleavage products of HCV
NS3p are inhibitors of the enzyme itself (Steinkühler et al., 1998).
Three inhibitors, which have been designed with such lead
Fig. 1. Chemical structures of protease inhibitors used in this study.
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clinical trials: BILN2061, VX-950 and SCH 503034 (De Francesco and
Carﬁ, 2007), conﬁrming that inhibition of NS3p is a viable strategy for
HCV therapy.
BILN2061 is a P1–P3 macrocyclic tripeptide that was the ﬁrst HCV
protease inhibitor to enter a clinical trial. It presents an inhibition
constant (Ki) for the genotype 1 enzymes in the sub-nanomolar range
and an EC50 in the genotype 1 HCV replicon system in the low
nanomolar range (Lamarre et al., 2003). In phase I clinical trials,
administration of BILN2061 to genotype 1 patients resulted in a 2–3
log reduction of HCV RNA in the majority of patients after 2 days of
dosing (Hinrichsen et al., 2004). However, the compound was less
effective on genotype 2 and 3 patients; only about half of this group
achieved more than a 1 log reduction in viral load (Reiser et al., 2003)
compared with 100% of the genotype 1 patients at the same dosing
level (Hinrichsen et al., 2004).
Mutagenesis studies have shown that the loss in inhibitory
potency on genotypes 3 vs. 1 by some compounds is caused by
naturally occurring amino acid substitutions in positions 168 or 123 of
the NS3p (Tong et al., 2006; Thibeault et al., 2004; Beyer et al., 2001).
These are the only two residues, involved in interactions with
inhibitors, which present a notably different side chain in the two
genotypes. Moreover, mutations at these positions are implicated in
the development of resistance to inhibitors in the genotype 1 protease
(Trozzi et al., 2003; Lu et al., 2004; Lin et al., 2004, 2005; Dahl et al.,
2006). In the genotype 1 NS3 protease, residues 168 and 123 are part
of a network of amino acids of alternating charges that starts with the
catalytic H57 and spans residues D81, R155, D168, and R123. These
last two residues are substituted by the uncharged Q168 and T123 in
the 3a genotype, thus interrupting the network of favorable
electrostatic interactions. In fact, the lack of a salt-bridge between
Q168 and R155 in the genotype 3 protease was invoked (Thibeault et
al., 2004) as the main factor contributing to the inhibitory potency
loss in vitro of BILN2061. However, to date no high resolution
structure exists for the NS3 protease of genotype 3, compared to the
almost thirty structures available for the 1b protease domain,
determined both by X-ray crystallography and NMR spectroscopy.
With the purpose of investigating at atomic resolution the structural
characteristics of the NS3 protease domain of genotype 3a (NS3p3a)
and the basis for its resistance to inhibition, we have used NMR
spectroscopy. Similarly to previous investigations using the P1–P3
inhibitor, BILN2061, we found that recently described potent P2–P4
macrocyclic inhibitors (Holloway et al., 2007; Liverton et al., 2008)
show a large decrease in potencywhen tested on NS3p3a with respect
to the 1b genotype NS3 protease (NS3p1b) (see Fig. 1, compoundsMa
and Mb, for examples). In contrast, a phenethylamide inhibitor,
(Fig. 1, compound Pa), shows no potency shift. The latter compound is
a close analog of an inhibitor for which we recently characterized the
interaction with NS3p1b (Gallo et al., 2009). Here we describe for the
ﬁrst time the overall structural characteristics of a soluble mutated
form of NS3p3a. This form of the protease contains seven surface
mutations that render soluble the protein and conserves the
inhibition proﬁle observed for the wild-type NS3p3a. We studied its
interactions with the phenethylamide Pa and the macrocyclic Ma
inhibitors, and with a peptide corresponding to the NS4A cofactor. In
addition, we describe the dynamical properties of the side chains of
residues 123 and 168 of NS3p3a and relate their structural
characteristics to the inhibitory potency loss observed for P2–P4
macrocyclic compounds like Ma and Mb.
Materials and methods
Expression and puriﬁcation of recombinant NS3 protease domains
All NS3p expression constructs were PCR-cloned into the pETM-11
vector (EMBL Heidelberg, Germany). Point mutations were intro-duced using the Quikchange site-directed mutagenesis kit (Strata-
gene). Protein production was performed in E. coli BL21 (DE3) cells
grown in LB medium supplemented with 0.05 mM ZnCl2 and induced
by 0.4 mM IPTG when the optical density was ∼0.6 (λ=600 nm).
After incubation with shaking at 21 °C overnight, cells were harvested
by centrifugation and resuspended in lysis buffer containing 40 mM
Tris pH 7.5, 200 mMNaCl, 0.5% (v/v) NP-40, 25% (v/v) glycerol, 6 mM
imidazole, 0.02 mM ZnCl2, 1 mM DTT. Cells were lyzed using a
microﬂuidizer and the NS3 proteins were puriﬁed from the soluble
fraction by Ni-afﬁnity chromatography (Ni-NTA resin, QIAGEN).
While attached to the resin, the buffer was exchanged for 40 mM
Tris pH 7.5, 200 mM NaCl, 0.1% (w/v) n-octyl-β-D-glucopyranoside,
10% (v/v) glycerol, 6 mM imidazole, 0.02 mM ZnCl2, 1 mM DTT,
followed by stepwise elution of the protein using the same buffer
supplemented with 50–250 mM imidazole. The yield and purity of
proteins were compared by reducing SDS-PAGE analysis followed by
staining with Coomassie brilliant blue R-250. The NS3p proteins
migrate at a position corresponding to their predicted monomeric
molecular weight of ∼23 kDa. The amount of insoluble protein
produced was monitored by using buffer supplemented with 2%
SDS to solubilize the pellet obtained by centrifugation of the lyzed
cells.
For the most soluble genotype 3a protein, M7, uniformly 15N- or
13C/15N-labeled proteins were produced in E. coli BL21 (DE3) cells
grown in M9 minimal medium supplemented with 0.05 mM ZnCl2
and containing (15NH4)2SO4 with or without 13C-labeled glucose. For
these NMR samples, the lysis buffer was 40 mM Tris pH 7.5, 200 mM
NaCl, 0.3% (w/v) CHAPS, 20% (v/v) glycerol, 1 mM DTT. During Ni-
resin puriﬁcation the buffer was exchanged for 40 mM Tris pH 7.5,
200 mM NaCl, 0.1% (w/v) CHAPS, 10% (v/v) glycerol, 1 mM DTT with
elution by imidazole as above. Following elution from the Ni-resin the
NS3 protein was incubated for 24 h at 4 °C with a solubility-enhanced
TEV protease (van den Berg et al., 2006) (plasmid kindly provided by
Dr. Helena Berglund) in order to remove the N-terminal 6His tag, with
simultaneous dialysis to remove imidazole. The dialysis buffer was 5%
(v/v) glycerol, 0.1% (w/v) CHAPS, 20 mM sodium phosphate pH 6.5,
100 mMNaCl and 1 mMDTT. The sample was subsequently re-passed
426 M. Gallo et al. / Virology 405 (2010) 424–438over a Ni-resin for removal of His-tagged species, including the TEV
protease. Finally, the sample was puriﬁed by size-exclusion chroma-
tography on a Superdex-75 (16/60) column equilibrated in dialysis
buffer.
The puriﬁed M7 samples were concentrated to 0.5 mM and
exchanged using NAP-5 columns (GE Healthcare) into the NMR
buffer containing 4% deuterated glycerol, 0.3% deuterated n-octyl β-D-
glucopyranoside, 20 mM sodium phosphate buffer pH 6.8, 100 mM
NaCl, 0.01% sodium azide and 1 mM DTT at 25 °C.
The NS4A peptide (4Ap) used in NMR experiments corresponds to
residues G21 to P39 of the NS4A protein of the 1b genotype, including
two lysine residues added at the termini to increase the solubility of
the peptide KKGSVVIVGRIVLSGKPAIIPKK (additional lysines are in
italics).
Final samples for NMR experiments contained 0.6–0.8 mM apo-
M7 or M7–Pa complex, 100 mM NaCl, 20 mM sodium phosphate pH
6.8, 1 mM DTT, 0.3% deuterated n-octyl β-D-glucopyranoside, 0.01%
sodium azide, in a solution of 90% H2O/10% D2O or 100% D2O.
Surface plasmon resonance (SPR)
All SPR experiments were performed using a Biacore 3000
instrument at 25 °C. Puriﬁed M7 protein in 10 mM sodium acetate
buffer pH 4.5 was covalently immobilized by amine-coupling on a
carboxymethylated dextran CM-5 sensor chip, yielding a surface
density of ∼1400 Response Units (RU). Experiments were performed
at a ﬂow rate of 40 μL/min in running buffer containing 40 mM
sodium phosphate pH 7.0, 150 mM NaCl, 0.05% n-octyl-β-D-glucopyr-
anoside, 0.1 mM DTT, 0.01 mM ZnCl2. Binding of NS4A-like peptides
was examined in multi-point titrations by injecting peptides at a
range of concentrations: 0, 0.05, 0.1, 0.5, 1.0, 5, 10, 20 and 40 μM, all
dissolved in running buffer. After each step, the sensor chip surface
was regenerated with a 1 min injection of 0.6% (v/v) surfactant P-20.
Data were analyzed using BIAevaluation software, with subtraction of
reference sensorgrams (injection of buffer only) to yield curves
representing speciﬁc binding. Steady-state analysis was used to
obtain thermodynamic dissociation constants (KD). Due to the
hydrophobicity of the wild-type NS4A cofactor peptides, lysine (K)
residues were added at both termini of the peptides used in the SPR
studies in order to enhance their solubility. Thus, the NS4A peptide 1b
(3 K) has the sequence KKKGSVVIVGRIVLSGKPAIIPKKK; and the NS4A
peptide 3a(3 K) has the sequence KKKGCVVIVGHIELGGKPALVPDKKK,
sequence differences between the two peptides are underlined,
additional lysines are in italics.
Inhibition assays
InhibitorsMa,Mb and Pawere chemically synthesized according to
published protocols (Liverton et al., 2008; Malancona et al., 2004). The
inhibition assays were performed by using the sensitive time-resolved
ﬂuorescence (TRF) assay capable of detecting very low NS3/NS4A
concentrations developed by Mao et al. (2008). Brieﬂy, NS3 was
solubilized in 100 μL of buffer containing 50 mMHepes pH 7.5, 150 mM
NaCl, 15% glycerol, 0.15% Triton X-100, 10 mM DTT, and 0.1% PEG. The
solutions containing the protease were preincubated with different
concentrations of inhibitors in DMSO for 30 min and for 15 min with
5 μM4Ap. Then the reactionswere initiatedbyadding100 nMof theTRF
substrate (Ac-Cys(Eu)-Asp-Asp-Met-Glu-Glu-Abu-[COO−]-X-Ser-Ala-
Lys(ε-QSY7)-NH2, where Eu and QSY7 are the ﬂuorescent and
quenching groups, respectively). The hydrolysis was quenched after
1 h at room temperature with 100 μL of 500 mM MES pH 5.5. Product
ﬂuorescence was detected with excitation at 340 nm and emission at
615 nm with a 400 μs delay in a Victor V2 ﬂuorophoteometer (Perkin
Elmer). The inhibition constants were derived using standard four-
parameter ﬁt to the data. Errors in the Ki constants measured are in the
low subnanomolar range.NMR spectroscopy
The NMR experiments were performed at 35 °C on Bruker
Avance700, Avance 600, and Avance400 spectrometers equipped
with triple resonance probes incorporating shielded z-axis gradient
coils. The NMR data were processed on Silicon Graphics workstations
using NMRPipe (Delaglio et al., 1995) and analyzed using NMRView
software (Johnson, 2004).
The following standard set of triple resonance spectra were
acquired in H2O: HNCO, HNCA, HN(CO)CA, CBCA(CO)NH, HBHA(CO)
NH and CBCANH and 15N-edited TOCSY. For the sample dissolved in
D2O the following experiments were performed: (H)CCH-COSY, H(C)
CH-COSY, (H)CCH-TOCSY, HACACO (Cicero et al., 2006). For gluta-
mine and asparagine side chain resonance assignment the following
experiments optimized for NH2 groupswere performed: HNCO, HNCA
and HACACO. Side chain resonance assignment was achieved for
almost all the T, Q, and N residues. The 15N-{1H} NOE experiment was
performed at 70.94 MHz 15N frequency using standard pulse schemes
(Kay et al., 1989) optimized for NH2 groups in an interleaved manner.
The heteronuclear NOE values were determined by the ratio of peak
volumes of spectra recorded with and without 1H saturation,
employing a net relaxation delay of 4 s for each scan in both
experiments. Errors were estimated by evaluating the standard
deviation of the NOE, σNOE:














where σIsat and σIunsat are the standard deviations of the noise in the
spectra. Errors were typically in the range 0.05–0.1.
Measurements of 15N T2 relaxation experiments were carried out
at 35 °C in a 400 MHz spectrometer using standard pulse schemes
(Kay et al., 1989) in an interleaved manner. Relaxation delays of 8, 24,
32, 40, 48, and 56 ms were employed. Data were ﬁtted using the Rate
Analysis routine of NMRView (Johnson, 2004). The uncertainties of
peak intensities were evaluated as the standard deviation of the
spectral noise measured in a region free of cross-peaks. Typically,
errors were about 6%.
Results
A soluble form of the 3a genotype NS3 protease
Production of NS3p3a (amino acids 1–180) using the procedure
previously described for obtaining NS3p1b, even after addition of a C-
terminal solubilizing lysine tail (residues ASKKKK) (Steinkühler et al.,
1998), yielded mostly protein in the insoluble fraction (Fig. 2A).
Efforts to refold the protein from the urea-denatured state were
unsuccessful. In view of these negative results, we engineered
mutants of NS3p3a to favor its production as a soluble protein for
structural studies. Fig. 2B shows the sequence alignment of the NS3
protease domains of genotypes 1 and 3. Residues close to the catalytic
site, substrate binding region or involved in the interaction with the
NS4A cofactor were left untouched. From the remaining residues we
selected a set of seven NS3p3a surface exposed residues (boxed in
Fig. 2B) to bemutated by introducing the corresponding residue of the
more soluble 1b genotype. The sequence of the resulting mutant
protein (hereafter termed M7) is shown at the bottom of Fig. 2B, and
with respect to the NS3p3a wild-type presents the sevenmutations at
the N-terminal domain (V28Q, T47C, G49N, H69G, L72T, A98T, and
A102S). These positions are distant from the catalytic site, as shown
when mapped onto a model of the structure of M7 in Fig. 2C.
As predicted, the mutations resulted in the production of a greatly
enhanced quantity of soluble protein that could be readily puriﬁed
(see Materials and methods, Fig. 2A). This is particularly relevant for
structural studies by NMR, for which a protein must reach
Fig. 2. Engineering a soluble form of the 3a genotype NS3 protease. (A) Direct comparison of the solubility of different NS3p proteins. SDS-PAGE analysis was used to compare the
yields of each NS3p protein present in the soluble fraction (partially puriﬁed from the cytosol; upper panel) and in the pellet (lower panel). The SDS-PAGE gels were stained with
Coomassie brilliant blue R-250 and are shown as grayscale images. The protein band at ∼38 kDa observed for the pellet indicates that the expression level of a non-NS3 protein was
similar in all cases. Key to lanes: (1) NS3p1b strain J, (2) NS3p3a wild-type, (3) NS3p3a− ST (ST indicates a solubizing tail added at the C-terminus of NS3p,−ASKKKK), (4) NS3p3a−
ST V28Q, (5) NS3p3a− ST T47C and G49N, (6) NS3p3a− STH69G and L72T, (7) NS3p3a− ST A98T and A102S, (8) M7, (9) Molecular Weight markers. (B) Multiple alignment of NS3p
sequences: NS3p1b (used in our previous NMR studies), NS3p3a, and M7 mutant used here. Positions that present a notable side chain switch between genotypes 1 and 3 are
grouped according to whether they are involved in the interaction with the NS4A cofactor (shaded light gray), if they are close to the catalytic or substrate binding region (shaded
light blue), or if they do not belong to the other two categories (shaded green). Seven residues from this group chosen to be mutated in M7 are boxed and indicated with an asterisk
at the bottom. The catalytic triad (H57, D81, and S139) is indicated in blue and highlighted by arrows. Residues at positions 123 and 168 responsible for the inhibitor potency shift
between both genotypes are in violet and highlighted by arrows. (C) Model of the structure of M7 showing the positions that were mutated from NS3p3a wt to achieve the soluble
form of the protease. Residues mutated are depicted in green, the catalytic triad in blue and residues 123 and 168 in violet. (D>) pKi values for inhibition of NS3/NS4A protease of
genotypes 1b, 3a and the mutant M7. Values are reported for inhibitors Ma,Mb and Pa, whose chemical structure is shown in Fig. 1, and BILN2061. Standard deviations in
measurements of pKi are too small to be appreciable in the log-scale graph (but were typically in the low subnanomolar range).
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tions appeared to be cumulative, since alternative ‘intermediate’
forms of NS3p3a each containing only one or two mutations showed
only mildly increased solubility compared to the wild-type NS3p3a
but were notably less soluble than the composite M7 protein. After
puriﬁcation, the M7 protein migrated as a single band in SDS-PAGE
with the appropriate apparent molecular weight, displayed a
monodisperse monomeric elution proﬁle in analytical gel ﬁltration
studies and gave the expected molecular weight by electrospray mass
spectroscopy (data not shown).
P2–P4 macrocyclic inhibitors Ma and Mb show a large potency shift
between 3a and 1b NS3 proteases
In order to assess whether the M7mutant retained the behavior of
the wild-type form of the protease with respect to inhibitor potency
shift, we tested the two NS3p3a proteins and the 1b genotype
protease with a series of inhibitors. Recently, potent macrocyclic
inhibitors of the NS3/NS4A protease were described, the design of
which was based on the formation of a P2–P4 linker, using an
isoquinoline moiety as the P2 group to facilitate the rapid synthesis of
analogs (Liverton et al., 2008). Compounds Ma and Mb depicted in
Fig. 1 are examples of these inhibitors, which show a Ki in the low
picomolar range on the 1b genotype NS3/NS4A enzyme (Liverton et
al., 2008). Both compounds were tested using the wild-type NS3/
NS4A enzyme of the 3a genotype and M7.
A Ki decrease of between two and three orders of magnitude with
respect to the 1b genotype enzymewas observed for both 3a enzymes
in the case ofMa (Ki 0.18 nM and 659 nM for the 1b and 3a genotypes,
respectively) and Mb, (Ki 0.05 nM and 20 nM) (Fig. 2D). This
inhibitory potency decrease is comparable to that of the BILN2061
inhibitor, for which a 200-fold change in Ki was observed between 1b
and 3a genotypes, when the inhibition assay was performed in the
same experimental conditions (Ki 0.32 nM and 65 nM).
We also tested an inhibitor presenting a less bulky P2 side chain
and lacking the P2–P4 cycle, like the phenethylamide inhibitor Pa
(Fig. 1) (Malancona et al., 2004). Compound Pa does not show a
signiﬁcant potency difference between 1b and 3a proteases and, as
observed for Ma and Mb, there is no signiﬁcant difference between
the wild-type and mutated 3a enzymes (Ki 0.40 μM, 0.35 μM and
0.31 μM for the 1b and 3a genotypes and M7, respectively) (Fig. 2D).
From these results we conclude that, as observed for wild-type
NS3p3a, the M7 protein retains the same decreased susceptibility to
inhibition by P2-exploiting compounds when compared to the
genotype 1b protease, and that the interaction between M7 and Pa
does not involve the key residues that cause this shift (123 and 168).
Binary complexes with Pa and Ma
M7 was produced uniformly 15N- or 15N/13C-labeled to charac-
terize its structure in solution by NMR spectroscopy. Fig. 3A shows the
1H–15N HSQC spectrum of M7. The quality of the spectrum is
acceptable for NMR studies, but we observed signs of sample
degradation at high protein concentrations, probably due to auto-
proteolysis.
A better quality NMR spectrum was obtained for the complex
between M7 and the phenethylamide inhibitor Pa (M7–Pa) (Fig. 3B).
Peaks in the HSQC spectrum appeared more disperse and more
homogeneous than in spectrum without the inhibitor. We have
recently reported that this type of inhibitor strongly stabilizes the N-
terminal domain of NS3p1b, and in particular the active site
conformation (Gallo et al., 2009). This fact is clearly reﬂected by the
presence of the two peaks corresponding to H57 and G58, at the
expected chemical shifts observed for other NS3p complexes with a
stabilized active site (Gallo et al., 2009; Archer et al., 2002; McCoy et
al., 2001). Using multinuclear NMR experiments that correlate thechemical shift of backbone nuclei, such as HNCO, HNCA, HNcoCA and
CBCAcoNH, we were able to assign 86% of the M7–Pa complex 1H, 13C
and 15N backbone nuclei. By analyzing the chemical shifts of Hα, Cα,
Cβ and C′ nuclei with the program TALOS (Cornilescu et al., 1999) we
determined the secondary structure of the M7–Pa complex (Fig. 3C).
The positions of the different elements of secondary structure
correspond very closely with those observed in all the crystal
structures for complexes of NS3p1b and with those of the complex
between NS3p1b and an analog of Pa (Gallo et al., 2009). Regarding
the N-domain, the secondary structure results indicate that the
introduction of the seven mutations that rendered the protein more
soluble did not change the structure of the protein, in line with the
fact that the inhibitor potency proﬁles on the mutant protein are very
similar to that on NS3p3a. In addition, the two key residues that are
responsible for the loss in inhibitory potency in the 3a genotype, T123
and Q168, are located in the same relative position in the C2 and F2
strands, respectively. Importantly, this indicates that the loss of
inhibition observed for compounds with large P2-substituents on the
3a vs. 1b protease is related to different chemical and/or conforma-
tional properties at the level of the side chains rather than a structural
change in the backbone conformation between the 1b and 3a
genotype proteases.
In the case of compound Ma, no structural data is available for
complexes with NS3p of any genotype, so we decided to study in
parallel its interaction with NS3p1b and M7. Ma interacts with both
proteases under the NMR conditions. However, the Ma complexes
demonstrate conformational ﬂexibility in solution, and probably also
aggregation effects, resulting in low T2 values that precluded a
detailed structural analysis (see Supplementary material, Fig. S1).
Nevertheless, the inhibitor binding region was determined for both
the 1b and 3a complexes (Fig. 4) by comparing the chemical shift of 1H
and 15N nuclei between Pa and Ma complexes. As expected, regions
showing chemical shift changes are located in the differential surface
of interaction of these inhibitors. In both genotypes the interaction of
compound Ma with NS3p occurs in the same region, indicating that
the orientation of the inhibitor in the protease complexes is the same
for both genotypes. In particular, the models show the different way
the R155–D168 region is used by the two inhibitors, with a direct
protein–ligand interaction with compound Ma but not Pa.
Fig. 5A shows selected regions of the 1H–15N HSQC spectra of Pa
and Ma complexes with the two proteases. In particular, a peak
corresponding to G58 was observed for the Ma complex with both
proteases. As mentioned before, the appearance of this cross-peak,
which is absent in the spectrum of the apo-protease, is an indication of
the stabilization of the active site produced by inhibitor binding.
Furthermore, residue 168 presents a different chemical shift in Pa and
Ma complexes with NS3p1b and M7 proteases. This difference
strongly suggests that this residue interacts only with Ma and not
with Pa. Interestingly, residue 123 presents almost the same chemical
shift in the two NS3p1b complexes, but a different chemical shift
between the two M7 complexes.
Interaction with NS4A peptides
Interaction of NS3p with its cofactor was investigated using
peptides spanning the central part of the NS4A protein belonging to
genotypes 1b and 3a (Lin et al., 1995). We ﬁrst tested the ability of a
23-mer peptide derived from the 3a genotype NS4A cofactor to
interact with M7, but no new peaks were detected (data not shown).
In contrast, the interaction of M7 with a peptide cofactor spanning
residues G21–P39 of the genotype 1b NS4A protein (termed 4Ap)
(Kim et al., 1996), provoked changes in the chemical shift of several
amide HN nuclei detected in the HSQC spectrum (Fig. 6). More
importantly, two peaks displaying the expected chemical shifts of H57
and G58 appeared in the M7–4Ap complex spectrum indicating a
stabilization of the active site by cofactor binding very similar to that
Fig. 3. Interaction ofM7proteasewith Pa. 1H–15NHSQC spectra on 15N-labeledM7alone (A), and after the addition of 1 equivalent of the phenethylamide inhibitor Pa (B). The presence of
diagnostic signals belonging to the active site, H57 and G58, are boxed. (A) was carried out at 25 °C and in the presence of 4% deuterated glycerol, while (B) at 35 °C and in the absence of
glycerol. (C) Secondary structure of NS3p complexes: NS3p1b–4Ap complex (PDB entry 1A1R, Kim et al., 1996), NS3p1b complexed with a phenetylamide inhibitor (Phen) analog of Pa
(PDBentry2K1Q, Gallo et al., 2009), and that observed forM7–Pa. Key residues for the inhibitorpotency shift between genotypes1band3a (positions 123 and168) are boxed.NMR signals
of residues 1–21 were not observed.
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these two cross-peaks with respect to the average intensity of the N–
H cross-peaks increased upon cofactor binding. This fact may indicate
a degree of active site stabilization induced by 4Ap, reﬂecting either
the disappearance of slow motions, and/or a reduced solvent
exchange rate. Further studies will be conducted in order to clarify
this point.
This improved binding to M7 of the peptide from genotype 1b
compared to that from genotype 3a was also observed in surface
plasmon resonance studies. In brief, using the M7 protein covalently
immobilized on a carboxymethylated dextran-coated sensor chip, a
steady-state afﬁnity analysis revealed a modestly enhanced binding of
the genotype 1b peptide (KD=1.9±0.3 μM) compared to the
genotype 3a peptide (KD=5.0±0.8 μM). Nevertheless, the spectrum
of the M7–4Ap complex at high protein concentrations was of poorquality, with heterogeneous line widths and an even faster degrada-
tion rate compared with apo-M7, precluding the study of this binary
complex at high resolution.
Interaction of M7–Pa with 4Ap induced changes in the chemical
shift of some peaks (Fig. 7). The 1H–15N HSQC spectrum was of an
intermediate quality between those of M7 and M7–Pa. Using the
assignment of M7–Pa we followed the chemical shift perturbation
caused by the interaction with the 4Ap cofactor. The perturbation is
very different in the N- and C-domains, as expected from the fact that,
in all known crystals, the cofactor binds to NS3p forming an extra β-
sheet in the N-domain. Fig. 7B shows regions of the 1H–15N HSQC
spectra of the binary and ternary complexes. Most of the residues that
show signiﬁcant perturbations are close to the cofactor in the
structures containing 4Ap (Fig. 7A). Conversely, the inhibitor binding
site is nearly unperturbed by 4Ap binding, particularly in the S-region
Fig. 4. Interaction of NS3p1b and M7 proteins with Ma. Chemical shift changes produced on M7 (A) and on NS3p1b (B) upon interaction with Ma, compared with the respective
complexes with Pa, are mapped on the structure of the protease. Residues whose chemical shift remains invariable in both complexes are depicted in blue; residues for which the
chemical shift is different in the Ma complex respect the Pa complex are depicted in red. Pa is designed in green and Ma in yellow. For the models, the structure of the complex of
NS3p1b with a close analog of Pa (PDB entry 2K1Q) was used as a basis. Ma was docked in the latter structure preserving the conserved inhibitor orientation that was observed in all
the available structures of NS3p1b–inhibitor complexes (Gallo et al., 2009). Residues of the charged network R123–D168–R155 are shown. The models show the different way the
two types of inhibitor interact with this region.
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chemical shift perturbation by 4Ap binding indicating that their
structural features do not depend on the presence of the cofactor.
The active site of M7 in the binary and ternary complexes
Residues H57 and G58, considered as markers of the stabilization
of the active site, do not show any large change in chemical shift upon
4Ap binding to the M7–Pa complex (Fig. 7B). In the case of H57, the
particular downﬁeld chemical shift of the amide hydrogen (close to
11 ppm) was rationalized as a consequence of a hydrogen bond withthe D81 side chain (McCoy et al., 2001). This situation is apparently
not altered by the cofactor, and only a slight upﬁeld shift is noticed. No
perturbation in chemical shift was observed for the other two
members of the catalytic triad (Fig. 7A), indicating that in the
presence or absence of 4Ap the conformation of the active site
induced by Pa is essentially identical.
A closer inspection of the active site is possible by monitoring the
low ﬁeld signal of the catalytic histidine δ1 proton (Fig. 8A). This peak
was not observed for free M7 or for the M7–4Ap complex, indicating
that, although the His-Asp dyad might be aligned by the cofactor, the
fast exchange with the solvent does not allow its observation. In
Fig. 5. Active site stabilization and interaction of positions 123 and 168 of NS3p1b andM7withMa. (A) Selected regions of the superposition of the 1H–15NHSQC spectra of theM7–Pa
(black) and M7–Ma (red) complexes showing cross-peaks corresponding to G58, T123 and Q168 in the M7–Pa complex. (B) The same for NS3p1b–Pa (black) and NS3p1b–Ma (red)
complexes.
431M. Gallo et al. / Virology 405 (2010) 424–438contrast, the signal is readily observable for the M7–Pa complex,
indicating that the inhibitor alone is able to align the His-Asp dyad and
shield the region from solvent exchange bymeans of the P2 side chain,
as already observed for other NS3p complexes (Gallo et al., 2009;
Barbato et al., 2000). The signal remains sharp at temperatures up to
35 °C, thus providing evidence of very slow exchange kinetics with
the solvent. Cofactor binding to form the ternary complex provokes a
very small downﬁeld shift of the signal. The tautomer of H57 in theFig. 6. Interaction of M7 and M7–Pa complex with 4Ap. 1H–15N HSQC spectra on 15N-labeled
both 4Ap and Pa (B). The presence of diagnostic signals belonging to the active site, H57 a
glycerol, while (B) at 35 °C and in the absence of glycerol.absence of 4Ap corresponds unambiguously to the Nδ1 protonated
form, as judged from the 1H–15N long-range HSQC spectrum (Pelton
et al., 1993) (Fig. 8B). This tautomer, although less populated than the
Nε2 protonated form of a solvent exposed histidine, is stabilized by
the interaction between H57 and D81. The chemical shift of Nδ1
reﬂects its participation as a strong hydrogen bond donor, whereas
Nε2 is not involved in any hydrogen bond interaction (Bachovchin,
1986). This situation remains almost unaffected upon 4Ap binding.M7 after addition of 1 equivalent of the 1b genotype 4Ap (A) and after the addition of
nd G58, are boxed. (A) was carried out at 25 °C and in the presence of 4% deuterated
Fig. 7. Chemical shift comparison between M7–Pa and M7–Pa–4Ap. (A) Chemical shift perturbation caused by 4Ap with M7–Pa interaction mapped onto the model for the ternary
complex. Residues showing perturbation are colored in red. Unperturbed residues are colored in blue. Residues for which the perturbation could not be established (prolines,
unassigned or overlapped residues) are colored in gray. Pa and 4Ap are depicted in green andmagenta, respectively. Side chains of residues of the catalytic triad (H57, D81, and S139)
and T123–Q168 are evidenced. The model was constructed using the crystal structure of NS3p1b–4Ap (PDB entry 1A1R) and the NMR structure of the complex NS3p1b with an
analog of Pa (PDB entry 2K1Q). (B) Selected regions of 1H–15N HSQC spectra of the M7–Pa complex obtained in the absence (blue) or presence (black) of 4Ap. The central and right
panels show the shift provoked on T123, Q168, H57 and G58 upon interaction with the cofactor.
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In view of the fact that Pa is able to strongly stabilize NS3p in
solution, and since this interaction does not involve residues 123 and
168, responsible for the loss of inhibitor potency on genotype 3a vs. 1b
by compounds with a large P2 substituent, we decided to study theconformational properties of these residues in the context of the M7–
Pa complex. The assumption is that these residues are present in the
same conformation in M7 and in M7–Pa. The goal of our study was to
establish whether there are differences in the dynamics of the side
chains of these two residues in the proteases of both genotypes before
interacting with inhibitors that exploit one or both positions for
Fig. 8. Effect of cofactor binding to M7–Pa on the imidazole ring nuclei of H57. Spectra of the M7–Pa complex in the absence or presence of the 4Ap peptide are depicted in blue and
black, respectively. (A) Chemical shift changes in the low ﬁeld signal belonging to the Nδ1-attached proton observed in the one dimensional 1H spectra. (B) 1H–15N long range HSQC
spectrum for the correlation of Hε1 and Hδ2 with Nδ1 and Nε2. The type of correlation corresponds to an Nδ1-protonated tautomer in both cases. H149 cross-peaks were not visible
in the conditions in which the spectrum of M7–Pa–4Ap was acquired.
433M. Gallo et al. / Virology 405 (2010) 424–438binding, in order to evaluate the role of entropy in the formation of the
complex.
A total of 14 out of 20 threonine side chains in theM7–Pa complex,
comprising T123, were assigned using standard 2D and 3D experi-
ments. Most of the non-assigned threonines belong to the ﬁrst 21
amino acids, which gave no detectable signals as in other NS3pcomplexes (Gallo et al., 2009, Barbato et al., 2000). As a simple
measurement of the dynamical behavior of the side chains, we used
the intensity of the Hβ–Cβ cross-peaks in the 1H–13C 2D constant-
time correlation experiment (Fig. S2A). In this experiment, the
intensity of the cross-peak is predominantly dictated by the 13C
transverse relaxation time T2 and therefore the larger the ﬂexibility of
434 M. Gallo et al. / Virology 405 (2010) 424–438the side chain, the more intense the cross-peak will result. Upon
examining these intensities for all threonines, T123, T160 and T177
appear to exhibit the greatest side chain ﬂexibility. As a support for
this analysis, peak intensities were related to the Accessible Solvent
Area (ASA) of the threonine side chain calculated using the high
resolution structure of NS3p1b as a model (Kim et al., 1996). It is
expected that solvent-exposed threonines will exhibit more ﬂexible
side chains leading to a direct relationship between ASA and the
cross-peak intensity. Fig. 9A shows the plot of ASA against peak
intensity, indeed revealing the expected correlation, with the three
ﬂexible threonine residues being the most solvent-exposed. There are
two notable exceptions from this behavior: T22 and T40, both
showing a diminished cross-peak intensity with respect to that
expected based on their solvent exposure in the structure of free
NS3p. T22 is the ﬁrst observed amino acid for M7: the ﬁrst 21 residues
are broad and not detectable, probably due to conformationalFig. 9. Side chain dynamics of T123 and Q168 key residues in the M7 protease. (A) Correlatio
threonine residues in a constant-time 1H–13C HSQC spectrum of theM7–Pa complex. (B) Obs
in the same complex. (C) Structure location and side chain mobility of selected threonine, g
mobility of their side chains and mapped on a model of the structure M7–Pa complex, based
and lowly mobile residues are indicated in red and blue, respectively. The respective side cha
depicted in green.exchange. It is possible that T22 shows a diminished intensity due
to a contribution of μs–ms movements. T40 is part of the inhibitor
binding site, and the presence of Pa therefore results in a lower ASA in
the complex with respect to that predicted by analysis of the free
NS3p structure.
Assignment of the side chain NH2 groups of glutamine (Q) and
asparagine (N) residues was possible for 9 of a total of 12 present in
M7 (Fig. S2B). To determine the degree of ﬂexibility that these side
chains show, we measured the 15N–{1H} NOE of the side chain NH2
group. For residues that do not show local mobility, NOE values close
to+0.8 are expected. Conformational ﬂexibility of the side chains will
translate into a signiﬁcant decrease of the NOE value. Fig. 9B shows
the heteronuclear NOE for the Q and N residues. Q8 and Q9 were
tentatively assigned based on the fact that these two glutamines show
chemical shift close to random coil values and that the heteronuclear
NOE values are between −2 and −3, indicating a very ﬂexiblen between Accessible Surface Area (ASA) and Hβ–Cβ cross-peak intensity for assigned
erved heteronuclear 15N–{1H} NOEs for assigned asparagines and glutamine NH2 groups
lutamine and asparagines residues. T, Q and N residues were classiﬁed according to the
on the structure of an analog inhibitor complexed to NS3p1b (PDB entry 2K1Q). Highly
ins are evidenced. S139, H57, D81 and R155 are also shown in light blue. Inhibitor Pa is
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whose backbone amide NH groups could not be detected in the HSQC
spectrum of the M7–Pa complex. Other very ﬂexible side chains are
those of N49 and Q80, which appear solvent exposed in a model of the
M7–Pa complex (see below). A heteronuclear NOE close to 0 was
observed for N27, Q168 and Q178, providing evidence of signiﬁcant
local mobility of the side chain. The only two side chains of Q and N
residues that show some degree of rigidity are those of Q41 and N77.
To rationalize these results, we have indicated the position of some
of these residues in the structure of a homology model for the M7–Pa
complex, built from the recently determined structure of an analogous
inhibitor bound to the NS3p1b (Gallo et al., 2009) (Fig. 9C). Q41 as
well as T40 are involved in the interaction with the phenyl ring of Pa,
and this fact explains the rigidity of the two side chains. Likewise, the
N77 side chain, which shows a large positive heteronuclear NOE,
participates in an interaction between the E1b-F1 β-strand and theα3
helix. This interaction is important to maintain the catalytic aspartate
aligned with the histidine residue (Kim et al., 1996; Barbato et al.,
1999). All the other N and Q residues resulted ﬂexible, and in the
structure are mostly solvent exposed, including N27, N49, Q80 and
Q178. Regarding the two key residues for the difference in inhibitor
afﬁnity T123 and Q168, they both resulted very mobile. This scenario
is expected to be very different for the 1b genotype, for which the
network of salt bridges R155–D168–R123 is likely to maintain the
three side chains in a more rigid conformation.Discussion
By using NMR spectroscopy we have performed the ﬁrst structural
characterization of the HCV NS3 protease belonging to the 3a
genotype. This characterization was made feasible by engineering
seven mutations of surface amino acids that rendered the protein
more soluble without changing its behavior against a panel of
inhibitors. As observed for NS3p3a, the mutated protein (M7) showed
a decreased susceptibility to inhibition by P2–P4 macrocyclic
inhibitors like compounds Ma or Mb compared to the 1b enzyme. In
addition, a linear inhibitor without large substituents at the P2
position, like the phenethylamide Pa, showed very similar potency on
all three NS3 proteins. Binding of the Pa inhibitor was also able to
structurally stabilize the protease, improving the quality of the NMR
spectra with respect to those recorded for the less stable free protease.
The phenyl ring of Pa confers a particular stabilization on the active
site by binding in the S1′ pocket, as previously observed for a complex
between NS3p1b and an analog of Pa (Gallo et al., 2009).
Two other potent NS3 inhibitors that are currently in clinical trials
are VX-950 and SCH-503034, also known as Velaprevir and
Boceprevir, respectively. In contrast to the inhibitors studied in this
work, BILN 2061, Ma and Mb, and Pa, which are all reversible non-
covalent inhibitors, VX-950 and SCH-503034 are reversible covalent
inhibitors. Structurally, VX-950 and SCH503034, are ketoamide linear
compounds, larger than Pa, with a P4 moiety interacting directly with
position 123 (Tong et al., 2006; Guo et al., 2006). However, regarding
the genotype potency shift, both VX-950 and SCH-503034 exhibit
approximately a 10-fold loss of potency against the 3a genotype with
respect to the 1b genotype (Flores et al., 2009), in comparison with
the more than 200-fold shift displayed by BILN 2061 and the two or
three orders of magnitude decrease of Ki for 3a vs. 1b genotype here
observed for Ma and Mb compounds. The reduced sensitivity to the
NS3 genotype of VX-950 and SCH-503034 was attributed to a greater
ﬂexibility of these acyclic inhibitors, which allow them to better adapt
to changes in the enzyme surface. The macrocyclic moiety confers to
BILN 2061, andMa andMb, a rigidity that is responsible of the greater
potency against genotype 1, but may render it more sensitive to
naturally occurring variations near the binding site (Tong et al., 2006;
Guo et al., 2006).In our earlier NS3p1b investigation we could not obtain evidence
about interaction between NS3p and peptides derived from its natural
cofactor NS4Ap (Gallo et al., 2009). Here, workingwith theM7 protein
and using the peptide cofactor from genotype 1b (4Ap), we have
observed an evident interaction and the corresponding stabilization of
the active site caused by the peptide. In fact, the cross-interaction
between 4Ap with NS3p3a, at least in the conditions of our study,
leads to a more clearly observable interaction than when using the
homologous 3a cofactor peptide. This is especially noteworthy
considering that in the two peptides, 13 out of 20 residues are
identical. However, this effect is not unprecedented: no sufﬁciently
stable complex has been so far obtained for the 1b genotype protease
with its cognate cofactor peptide for NMR studies (Archer et al., 2002;
Cicero et al., 1999), but the 2a genotype NS3 protein was able to
interact with the genotype 1b cofactor giving rise to a stable complex
in solution (Wright-Minogue et al., 2000), which could be further
stabilized by interaction with an inhibitor (Archer et al., 2002). In line
with our results, it was recently noted that in one case NS3p3a was
over two-fold more active in the presence of the NS4A cofactor of
genotype 1b, than in the presence of cofactors from any other
genotype, including its proper cofactor. Indeed, this pairing was the
most active cross-genotypic combination in 28 heterologous interac-
tions tested (Franco et al., 2008).
Our results strongly indicate that Pa and 4Ap produce a very
similar conformation of the active site, as judged by the chemical
shifts observed for the amide HN nuclei of H57 and G58, the low ﬁeld
signal corresponding to H57 HNδ1, and the two nitrogen nuclei of the
imidazole ring of the M7–Pa and M7–4Ap–Pa complexes. These
results strengthen our ﬁndings that binding to the S′ pockets, in a
similar way to the binding mode of the substrate, can induce an active
site conformation that is very similar to that predicted for the
protease–cofactor complex in terms of catalytic triad alignment (Gallo
et al., 2009). In addition, our data show that the conformational
properties of the two residues responsible for the inhibitor potency
shift, 123 and 168, are not affected by cofactor interaction, indicating
that their conformational properties in the binary complexM7–Pa can
be extrapolated to the more physiologically relevant ternary complex,
M7–Pa–4Ap.
Interaction of NS3p with the macrocyclic inhibitor Ma yielded
conformationally unstable complexes with proteases belonging to
genotypes 1b and 3a. However, the active site shows signs of
stabilization as suggested by the appearance of the signal belonging
to G58. Our chemical shift perturbation data indicate that the
structures of the two Ma complexes are very similar. This similarity
suggests that the different chemical nature of residues 123 and 168 is
not favoring a different binding mode of macrocyclic inhibitors.
Considering that the two ﬁnal states do not differ, it is likely that
differences in the conformational features of the two proteins that
precede the interaction play a signiﬁcant role in determining the
change in afﬁnity of Ma for NS3p1b and NS3p3a.
The structural basis for this differential inhibition proﬁle between
proteases of the 1b and 3a genotypes is still an open question,
although some hints are emerging (Beyer et al., 2001; Courcambeck
et al., 2006; Guo et al., 2006; Thibeault el al., 2004; Tong et al., 2006;
Lin et al., 2004, 2005; Trozzi et al., 2003). The proteins belonging to
the two genotypes show a high degree of amino acid identity (75.8%
average, see Fig. S3). As already discussed, some studies have
identiﬁed residues in position 123 and 168 to be the cause of this
potency shift (Tong et al., 2006; Thibeault et al., 2004; Beyer et al.,
2001). To shed light on this subject, our purposewas to study how this
region is presented to the macrocyclic inhibitor and more speciﬁcally
how the dynamics of these residues in the free enzymemay affect the
binding afﬁnity for the P2–P4 macrocyclic inhibitors. To this end, we
used the Pa–NS3p complex as a model for the free protein, based on
the lack of interaction of Pa with residues 123 and 168 as shown by
the high-resolution structure of the NS3p1b–Pa analog complex
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potency that inhibitor Pa exhibits on both genotype enzymes.
Binding of P2–P4 macrocyclic compounds Ma and Mb, presenting
an extra substituent in P2, is expected to involve more directly the
region containing amino acids 155–123–168. As no structures of this
type of inhibitor bound to the NS3 protease are currently available,
and because complexes between this enzyme and Ma are not
amenable to detailed structural analysis by NMR, we generated a
model of the NS3 protease–Ma complex. In this model, the linker
between the P2 and P4 side chains lies just over Q168 of NS3p3a and
over D168 of NS3p1b. This direct interaction explains our observed
chemical shift differences for this residue between the M7–Pa and
M7–Ma complexes, and contributes in turn to the decrease in Ki for
Ma andMb. The same kind of interaction of the side chain of D168was
observed in a complex of NS3p1b with a P2–P4 macrocyclic inhibitor
bearing a bulky P2 substituent 4-hydroxyproline (Arasappan et al.,
2006). For position 123, the interaction with P2–P4 macrocyclic
inhibitors is not direct. In the case of genotype 1b, which presents a
pre-organized 155–168–123 region to interact with this kind of
inhibitors, there is no signiﬁcant chemical environment change
around this residue upon binding, in line with the lack of chemical
shift difference between NS3p1b–Pa and –Ma complexes. In contrast,
in the 3a genotype protease there is a considerable conformational
change around residue 123 when the enzyme binds the inhibitor,
causing the observed chemical shift difference between M7–Pa and
M7–Ma.
In the context of the S2 pocket of NS3p, interaction of the
isoquinoline ofmacrocyclesMa andMbwith R155 is expected to force
an extended conformation of its side chain, favoring the formation of a
salt-bridge R155–D168 in NS3p1b (Courcambeck et al., 2006;
Tsantrizios et al., 2003; Guo et al., 2006). The lack of this salt-bridge
in NS3p3a, due to the D168Q substitution, may be one of the factors
contributing to the decrease in afﬁnity for compounds bearing a bulkyFig. 10.Model for the loss of entropy produced in the NS3p from genotype 3a but not from g
and in the complex with Ma. Side chains of residues R155, Q168 and T123 are evidenced. M
ﬂexible. In the complex with Ma, R155 and Q168 directly interacting with the inhibitor are i
and R123 are evidenced. These residues are rigid in the apo-NS3p1b and continue to be rigP2 substituent (Tong et al., 2006). A second effect is the increase in the
solvation of R155 when the partially neutralizing negative charge of
D168 is removed (Trozzi et al., 2003). Binding of inhibitors making
extensive contacts with R155 side chain will need to pay an energetic
price in order to desolvate the charged group, which will be more
solvated in the absence of a salt bridge with D168. However, in the
context of NS3p3a protease R123 is also mutated into a neutral amino
acid (threonine), preserving the net charge of the region. This in turn
explains why the BILN2061 inhibitor shows a slightly higher afﬁnity
for a NS3p3a/1b chimera inwhich both amino acids 123 and 168were
mutated than for the single-mutated D168Q enzyme (Thibeault et al.,
2004).
Our results point to a third effect, involving the ﬂexibility of T123
and Q168 side chains in the 3a protein. In addition to a non-ideal
conformation for inhibitor binding, one has to consider also the
conformational freedom that will be lost upon inhibitor binding,
particularly for Q168 in the case of compounds Ma and Mb, or T123
for inhibitors like hexapeptides (Beyer et al., 2001). From the
secondary structure analysis performed here (Fig. 3C), the overall
structure of the M7–Pa complex is very similar to that of the
corresponding 1b enzyme, suggesting that the reason for the different
inhibitor proﬁles of the two proteins by the P2–P4 macrocycles may
reside at the level of side chain chemical and conformational
properties. Therefore, it is the dynamical behavior of the side chains
of these two key residues, T123 and Q168, which adds another piece
of information to aid the construction of an atomic model that
explains the differences in inhibitory potency of some compounds on
the 1b vs. 3a NS3 protease. Fig. 10 and Table 1 summarize our model
for the loss of entropy produced in the 3a but not in the 1b genotype
NS3p when binding inhibitors that exploit residues 123 and/or 168
for the interaction. In the case of NS3p3a, side chains of residues T123,
Q168, and possibly R155 are ﬂexible. When the complex is formed,
the large P2 substituent of the inhibitor interacts with R155 and Q168,enotype 1b when binding P2–P4 macrocyclic inhibitors. (A) NS3p3a in the free protein
a is depicted in yellow. In the free protein residues Q168, T123 and, possibly, R155 are
n a rigid conformation. (B) The same for NS3p1b. The interactions between R155, D168
id upon binding Ma.
Table 1
Model for the loss of entropy associated with the genotype 1b vs. 3a NS3p inhibitor potency shift.
Inhibitor Potency shift between
1b and 3a genotypes
Interaction with
residues 123/168
Side chain residues 123/168 dynamics
NS3p1b NS3p3a
Pa No No 123 rigid/168 rigid 123 ﬂexible/168 ﬂexible
Ma, Mb Yes 123 indirect/168 direct 123 rigid/168 rigid 123 not known/168 rigid
437M. Gallo et al. / Virology 405 (2010) 424–438which experience a transition from a mobile to a rigid conformation.
Therefore, binding of these compounds will impose a decrease in side
chain mobility with a consequent entropic penalty. The situation is
very different for the genotype 1b, where such an entropic price is not
necessary for binding of Ma or Mb to the enzyme, because the two
consecutive salt bridges will maintain the side chains of R123, D168,
and R155 in rigid positions.
In conclusion, our results have generated a plausible explanation
for the observed loss in potencywhen comparing inhibitors of the NS3
proteases from HCV genotypes 1 and 3, with ramiﬁcations for the
evaluation and improvement of potentially therapeutic pan-genotype
compounds currently under development. For example, NS3p1b
presents a rigid and ﬂat surface around the S2 and S4 pockets that
ultimately led to the identiﬁcation of inhibitors with ﬂat and bulky
substituents in P2 and P4 positions. Such a strategy produces less
potent inhibitors of the 3a genotype NS3 protease and additional
favorable interactions are needed to counterbalance the entropic
penalty imposed by ﬂexible side chains of this region in NS3p3a.
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